IRB #

IRB00007471

Title

North American Study of Epistaxis in HHT (NOSE)

Principal Investigator

Nathan Sautter

Study Purpose

The purpose of this study is to learn if the following nose sprays could reduce the frequency of nosebleeds in subjects with hereditary hemorrhagic telangiectasia (HHT): estriol, tranexamic acid, and bevacizumab.

Medical Condition(s)

hereditary hemorrhagic telangiectasia (HHT)

Eligibility Criteria

-Those with nosebleeds that last at least 1 minute long (on average) and occurs at least once a week when averaged during past 8 weeks
-18 years or older

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

24 weeks total, with 12 weeks of treatment period and 12 weeks off therapy

Minors Included

No

Contact

Phyllis Carello at 503-494-0164 and Carrie Farrar at 503-494-4233

Sponsor

Hereditary Hemorrhagic Telangiectasia Foundation

Recruitment End

06/30/2013

Compensation Provided

No